Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 10000 shares trading hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Price Performance
The business has a 50-day moving average of C$0.02 and a 200 day moving average of C$0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The firm has a market capitalization of C$1.33 million, a P/E ratio of -1.00 and a beta of 0.05.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last released its quarterly earnings data on Thursday, August 29th. The company reported C($0.01) EPS for the quarter. The firm had revenue of C$0.16 million during the quarter. On average, sell-side analysts predict that Aequus Pharmaceuticals Inc. will post -0.1 earnings per share for the current fiscal year.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
See Also
- Five stocks we like better than Aequus Pharmaceuticals
- How to Buy Cheap Stocks Step by Step
- When Is the Best Time to Invest in Mutual Funds?
- Buy P&G Now, Before It Sets A New All-Time High
- Is NVIDIA Stock in a Correction or Consolidation?
- P/E Ratio Calculation: How to Assess Stocks
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.